Hubert Serve
Overview
Explore the profile of Hubert Serve including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
284
Citations
10156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
2.
Lang F, Voss A, Kobbe G, Junghanss C, Beck J, Viardot A, et al.
Leuk Lymphoma
. 2025 Feb;
:1-9.
PMID: 39921529
Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA)...
3.
Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, et al.
Eur J Cancer
. 2025 Feb;
218:115266.
PMID: 39893747
Background: In patients with unresectable, stage III non-small cell lung cancer (NSCLC), durvalumab maintenance after concurrent chemoradiotherapy (cCRT) was shown to improve survival over placebo. As subgroup analyses indicated better...
4.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann J, Seidl C, et al.
Front Immunol
. 2024 Dec;
15:1413927.
PMID: 39737173
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an...
5.
Kessel J, Bug G, Steffen B, Brunnberg U, Vehreschild M, Weber S, et al.
Infection
. 2024 Dec;
PMID: 39699836
Purpose: Bloodstream infections caused by Pseudomonas aeruginosa (PABSI) in hematological patients are associated with high morbidity and mortality. We investigated the epidemiology, risk factors, and outcomes of PABSI at our...
6.
Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J, et al.
Ann Hematol
. 2024 Nov;
103(12):5387-5393.
PMID: 39589497
Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is rare, but prognostically extremely unfavorable and associated with very high mortality rates. Aim of our single-center study was to...
7.
Recher C, Dumas P, Berard E, Tavitian S, Leguay T, Galtier J, et al.
Am J Hematol
. 2024 Nov;
100(1):23-32.
PMID: 39555737
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of...
8.
Muhs C, Alshamleh I, Richter C, Serve H, Schwalbe H
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518017
Metabolism plays a central role in cancer progression. Rewiring glucose metabolism is essential for fulfilling the high energy and biosynthetic demands as well as for the development of drug resistance....
9.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
10.
Rollig C, Steffen B, Schliemann C, Mikesch J, Alakel N, Herbst R, et al.
J Clin Oncol
. 2024 Sep;
43(1):65-74.
PMID: 39284116
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60...